IVA on Nasdaq

Inventiva S.A.

Pharmaceutical preparations company, listed on Nasdaq (IVA). Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Nanobiotix S.A., Ascendis Pharma (Denmark) or Evotec SE, or pick any stock.

  • TickerIVA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersI01
  • Incorporated inFrance2
  • Business address50 Rue De Dijon, Daix, I0 211212
  • Filer categoryAccelerated filer2

See how the biggest companies compare on our leaderboards

We were founded in 2011 and incorporated in France in 2016 under the legal name Inventiva S.A. as a société anonyme, or S.A., for a period of 99 years. Our principal executive offices are located at 50 rue de Dijon, 21121 Daix, France and our telephone number is +33 3 80 44 75 00. We are registered at the Dijon Trade and Companies Register ( Registre du commerce et des sociétés ) under the number 537 530 255. Our agent for service of process in the United States is Cogency Global Inc., 122 East 42nd Street, 18th Floor, New York, New York 10168.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2024

-1060.6%Operating margin4
-47.4%Revenue growth, 20244

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Research and development88¢90.9M EUR
  • Interest12¢12.2M EUR
  • Income tax0¢313.0K EUR

Out of 9.2M EUR in revenue.4

Financial statements

Revenue567849.2M EUR in 2024+188% since 2018
05.0M EUR10.0M EUR15.0M EUR20.0M EUR2018: 3.2M EUR3.2M EUR20182019: 7.0M EUR7.0M EUR2019+119%2020: 372.0K EUR372.0K EUR2020−95%2021: 4.2M EUR4.2M EUR2021+1027%2022: 12.2M EUR12.2M EUR2022+190%2023: 17.5M EUR17.5M EUR2023+44%2024: 9.2M EUR9.2M EUR2024−47%
Operating income56784-97.6M EUR in 2024+197% since 2018
-150.0M EUR-100.0M EUR-50.0M EUR02018: -32.9M EUR-32.9M EUR20182019: -30.3M EUR-30.3M EUR2019−8%2020: -29.7M EUR-29.7M EUR2020−2%2021: -52.1M EUR-52.1M EUR2021+75%2022: -57.1M EUR-57.1M EUR2022+10%2023: -102.7M EUR-102.7M EUR2023+80%2024: -97.6M EUR-97.6M EUR2024−5%

Every line of the income statement as filed: the last 3 fiscal years, latest first.9

Period ending2025-12-312024-12-312023-12-31
Revenues4.5M EUR9.2M EUR17.5M EUR
Other income3.4M EUR5.5M EUR5.7M EUR
Total revenues and other income7.9M EUR14.7M EUR23.2M EUR
Research and development costs-87.0M EUR-90.9M EUR-110.0M EUR
Marketing - Business development expenses-5.0M EUR-2.0M EUR-2.0M EUR
General and administrative expenses-47.9M EUR-15.8M EUR-13.8M EUR
Other operating income (expenses)-9.0M EUR-3.6M EUR-44.0K EUR
Operating profit (loss)-141.0M EUR-97.6M EUR-102.7M EUR
Financial income4.2M EUR2.9M EUR1.8M EUR
Financial expenses-216.9M EUR-88.9M EUR-6.9M EUR
Financial income (loss)-212.8M EUR-86.0M EUR-5.1M EUR
Share of net profit (loss) - Equity method-350.0K EUR-313.0K EUR-2.0M EUR
Income tax-22.0K EUR-313.0K EUR-607.0K EUR
Net loss for the period-354.1M EUR-184.2M EUR-110.4M EUR
Basic loss per share-1.90 EUR-3.08 EUR-2.43 EUR
Diluted loss per share-1.90 EUR-3.08 EUR-2.43 EUR
Weighted average number of shares outstanding used to calculate basic loss per share186.8M shares59.8M shares45.4M shares
Weighted average number of shares outstanding used to calculate diluted loss per share186.8M shares59.8M shares45.4M shares

Compare Inventiva S.A. with another company

Filings

176 filings to the SEC since October 2021: 5 annual reports, 37 large holders, 134 other. The latest 20:

  1. Oct 6, 20266-K EDGAR
  2. Sep 28, 20266-K EDGAR
  3. Sep 3, 20266-K EDGAR
  4. Sep 1, 20266-K EDGAR
  5. Jul 30, 20266-K/A EDGAR
  6. Jul 29, 20266-K EDGAR
  7. Jul 9, 20266-K EDGAR
  8. Jul 6, 20266-K EDGAR
  9. Jun 12, 20266-K EDGAR
  10. Jun 12, 20266-K EDGAR
  11. Jun 9, 20266-K EDGAR
  12. Jun 3, 20266-K EDGAR
  13. Jun 3, 20266-K EDGAR
  14. Jun 2, 2026424B5 EDGAR
  15. Jun 2, 2026FWP EDGAR
  16. Jun 2, 2026F-3ASR EDGAR
  17. May 26, 20266-K EDGAR
  18. May 22, 20266-K EDGAR
  19. May 15, 2026SCHEDULE 13G/A EDGAR
  20. Apr 22, 20266-K EDGAR

The 176 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 86. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Caligan Partners LP8,163,191$30.9M1.5%+3,188,285
Samsara Biocapital, LLC6,314,805$23.9M2.0%+1,120,000
Nantahala Capital Management, LLC5,372,786$20.3M0.6%New
Paradigm Biocapital Advisors LP4,000,000$15.1M0.3%No change
Andera Partners3,633,181$13.7M6.7%+1,815,000
ADAR1 Capital Management, LLC3,606,656$13.6M0.6%+1,432,258
Millennium Management LLC3,512,174$13.3M0.0%+524,561
Trails Edge Capital Partners, LP2,657,997$10.0M1.6%No change
Franklin Resources Inc2,642,611$10.0M0.0%+181,046
Squadron Capital Management LLC2,435,000$9.2M3.2%+1,900,000
Woodline Partners LP2,323,149$8.8M0.0%New
Aberdeen Group plc2,307,773$8.7M0.0%New
UBS Group AG2,305,192$8.7M0.0%−13,501
Boothbay Fund Management, LLC2,003,782$7.6M0.1%+533,375
Patient Square Capital LP1,967,171$7.4M1.2%New
NEXTBio Capital Management LP1,787,984$6.8M3.1%+454,500
Citadel Advisors LLC1,784,566$6.7M0.0%+1,719,616
Ameriprise Financial Inc1,697,148$6.4M0.0%+852,933
Point72 Asset Management, L.P.1,683,012$6.4M0.0%+726,791
Integral Health Asset Management, LLC1,520,000$5.7M0.2%+1,120,000
Yu Fan1,500,000$5.7M5.3%No change
NEA Management Company, LLC1,462,586$5.5M0.3%No change
Stempoint Capital LP1,426,320$5.4M0.9%New
Propel Bio Management, LLC1,281,212$4.8M2.5%+556,534
Kingdon Capital Management, L.l.c.1,270,000$4.8M0.6%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22